We report on the ASCO Annual Meeting 2021!
We highlight some of the key news presented each day during the meeting – and soon we will be with Dr. Milind Javle speaking to highlight the latest gastrointestinal cancers, and Dr. Erika Hamilton to share her insight on the biggest breast cancer summaries.
Welcome to the OncLive news network! I’m Gina Mauro.
Data from the phase 2 NIFTY study showed that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free and overall survival for patients with metastatic bile duct cancer whose disease had progressed after first-line gemcitabine/cisplatin.
Camrelizumab in combination with chemotherapy demonstrated an improved overall and progression-free survival, as well as a manageable safety profile, as first-line therapy versus placebo/chemotherapy in patients with advanced or metastatic squamous cell carcinoma of the esophagus. The data was from the ongoing Phase 3 ESCORT-1st study.
In breast cancer, ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor positive, HER2-negative advanced disease after nearly 5 years of follow-up, regardless of whether patients received the regimen in the first or second-line setting, as shown in an exploratory analysis of the phase 3 MONALEESA-3 trial.
Similarly, palbociclib plus fulvestrant was shown to maintain a clinically meaningful improvement in overall survival compared to placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer at a median follow-up of 73.3 months from phase 3 PALOMA-3 process.
In the Phase 2, single-arm National Cancer Institute-Children’s Oncology Group Pediatric MATCH study, cohort findings showed that selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had useful mutations in the RAS/RAF/MAPK1/2-ERK trajectory.
Be sure to check out more of our coverage of the 2021 ASCO Annual Meeting on OncLive.com.
That’s all for today. Catch us tomorrow where we will sit down with Dr. Nick Vogelzang to highlight some pivotal studies on genitourinary cancers, as well as Dr. Erin Crane who will share some intriguing perspectives on gynecological cancers.
Thanks for watching OncLive News Network: On Location, I’m Gina Mauro.